GlobeNewswire

Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019

Share

Allschwil, Switzerland – August 23, 2019 

Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France.

Idorsia’s aprocitentan
An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online.

Idorsia’s selatogrel
An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of the "New developments in anti-thrombotic drug therapy" session with a focused discussion with the lead author, Professor Robert Storey, BM, Professor of Cardiology, University of Sheffield, UK, at 17:15 on September 1, 2019. The abstract can be found online.

A second oral presentation entitled "Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: A randomised open-label phase 2 study", will be part of the "Emerging treatments in acute coronary syndromes" session with a focused discussion with the lead author, Professor Peter Sinnaeve, MD, Department of Cardiology, University Hospitals Leuven, Faculty of Medicine, University of Leuven, Belgium, at 11:34 on September 3, 2019. The abstract can be found online.

In addition, Idorsia representatives will be present at Stand B320 from 10:00 - 17:00 on Saturday, August 31, until Tuesday, September 3.

_______________

Notes to the editor

About aprocitentan
Aprocitentan is an orally active dual endothelin receptor antagonist, which is being investigated for patients whose hypertension is uncontrolled despite the use of three or more antihypertensive drugs.

In June 2018, Idorsia initiated PRECISION, a multi-center, double-blinded, placebo-controlled, randomized, parallel-group, Phase 3 study to demonstrate the antihypertensive effect of aprocitentan when added to standard of care in patients with resistant hypertension. Idorsia, in consultation with regulatory agencies, has designed a single study which will efficiently address both the short-term efficacy of aprocitentan and the durability of its effects in long-term treatment.

Patients with a history of resistant hypertension will undergo a thorough screening and run-in period. This will confirm the diagnosis of resistant hypertension by excluding pseudo or apparent resistant hypertension. During the screening period, the patient’s background antihypertensive therapies will be transitioned to a standardized fixed combination of a calcium channel blocker (amlodipine), an angiotensin receptor blocker (valsartan), and a diuretic (hydrochlorothiazide).

Patients with true resistant hypertension will then be randomized to receive aprocitentan 12.5 mg, 25 mg, or placebo once-daily. The study consists of 3 sequential treatment periods. The first is a double-bind treatment period designed to demonstrate the effect of aprocitentan on blood pressure at Week 4, compared to placebo. Patients then enter a treatment period where they are treated with aprocitentan 25 mg for 32 weeks. This is followed by a double-blind, randomized withdrawal treatment period where patients will remain either on aprocitentan 25 mg or switch to placebo for 12 weeks. The latter treatment period is designed to demonstrate the durability of the blood pressure lowering effect of aprocitentan. Patients will then enter a 30-day safety follow-up period.

From the initial screened patient population, at least 600 patients will be randomized and at least 300 patients are expected to complete the study. The study will be conducted in approximately 100 sites in around 20 countries.

In December 2017, Janssen Biotech, Inc. entered into a collaboration agreement with Idorsia to jointly develop and commercialize aprocitentan and any of its derivative compounds or products. Both parties have joint development rights over aprocitentan. Idorsia will oversee the Phase 3 development and regulatory submission. The costs will be shared equally between both partners. Janssen will oversee the Phase 3 development and submission for any additional indications.

Aprocitentan at ESC-19
Oral presentation:
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension.
Session: Drug treatment in hypertension – new insights, 34.
P Danaietash, P Verweij, B Flamion, J Menard, M Bellet; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, Clinical Investigation Centre, Inserm /Assistance Publique, Hôpitaux de Paris, Hôpital Européen and Université Paris-Descartes, Paris, France.
Saturday, August 31, 2019, 09:54 - 10:12

About selatogrel
Selatogrel is a highly-selective P2Y12 receptor antagonist developed for acute coronary syndrome.

Two Phase 2 studies in patients with stable coronary artery disease and acute myocardial infarction, respectively, have met their pharmacodynamic objectives of significantly inhibiting platelet aggregation. Subcutaneous administration of selatogrel 8 mg and 16 mg has demonstrated a rapid onset of action, within 15 minutes, with the height of its effect extending over 4-8 hours, depending on the dose. The predefined extent of platelet aggregation inhibition was seen in at least 89% of the patients in both chronic and acute situations across doses. Selatogrel was safe and well tolerated in both studies and there were no treatment-emergent serious bleeds. Idorsia is now preparing for the end of Phase 2 meetings with health authorities where it will discuss a Phase 3 study.

Selatogrel at ESC-19
Oral presentation:
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients.
Session: New Developments in Anti Thrombotic Drug Therapy, 2349.
Robert Storey, Paul Gurbel, Stefan James, Jurrien ten Berg, Jean-Francois Tanguay, Corine Bernaud, Jean-Marie Frenoux, Abdel Hmissi, Mike Ufer, Pim Van der Harst, Arnoud Van't Hof, George Dangas, Vijay Kunadian, Diana Gorog, Dietmar Trenk, Dominick Angiolillo.
Sunday, September 1, 2019, 17:15 - 17:32

Oral presentation:
Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: A randomised open-label phase 2 study.
Session: Emerging Treatments in Acute Coronary Syndromes, 5232.
Peter Sinnaeve, Gregor Fahrni, Dan Schelfaut, Alessandro Spirito, Christian Mueller, Jean-Marie Frenoux, Abdel Hmissi, Corine Bernaud, Mike Ufer, Tizziano Mocetti, Shaul Atar, Marco Valgimigli.
Tuesday, September 3, 2019, 11:34 - 11:48

About Idorsia
Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Result of Riksbank´s purchases of Commercial Paper27.5.2020 10:00:00 CESTPress release

Auction date200527Requested volume, SEK mln4,000 Credit rating class1Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.55 %Total bid amount, SEK mln150 MioPrel. accepted volume, SEK mln150 MioPercentage alloted100.00 %Number of bids1 Credit rating class1Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.65 %Total bid amount, SEK mln0,000Prel. accepted volume, SEK mln0,000Percentage alloted100.00 %Number of bids0 Credit rating class2Term3MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.85 %Total bid amount, SEK mln375 MioPrel. accepted volume, SEK mln375 MioPercentage alloted100.00 %Number of bids2 Credit rating class2Term6MRequested volume, SEK mln1,000 +/-Fixed purchase rate0.95 %Total bid amount, SEK mln250 MioPrel. accepted volume, SEK mln250 MioPercentage alloted100.00 %Number of bids2

Adevinta Ventures invests in MEDWING’s €28 million Series B funding round27.5.2020 09:09:17 CESTPress release

Oslo, 26 May 2020 - Adevinta, through its Adevinta Ventures team, is investing for a second time in MEDWING, one of Europe’s leading healthtech companies, in a €28 million Series B funding round, led by Cathay Innovation, with participation from historical investors Northzone, Atlantic Labs and Cherry Ventures. This follows on from Adevinta’s first investment from December 2018. Founded in 2017 and based in Berlin, MEDWING aspires to make working in the healthcare sector more attractive and to solve the shortage of healthcare personnel. The company empowers candidates to work in a flexible way to suit their lifestyle and supports hospitals. They help with the recruitment process and human resources management by applying innovative matching, communication technology and personal consultations. Ovidiu Solomonov, VP Global Markets and Ventures at Adevinta, says: “Medwing gives power, autonomy and transparency to nurses, addressing some of the inefficiencies in the healthcare staffing ind

Notice to attend Elanders’ Annual General Meeting 202027.5.2020 09:00:00 CESTPress release

Shareholders in Elanders AB (publ) are invited to attend the Annual General Meeting on Thursday 25 June 2020 at 10 a.m. at Södra Porten, Flöjelbergsgatan 1 C, Mölndal, Sweden. INFORMATION IN RELATION TO COVID-19 (CORONAVIRUS) In view of the ongoing spreading of the coronavirus, a number of precautionary measures are being taken in connection with the Annual General Meeting to reduce the risk for the shareholders and other persons attending the Meeting: Registration will not begin until 09.30 a.m.No food or drinks will be served. No gifts will be handed out.The address by the President will be kept very short.With a few exceptions, the Board of Directors and senior executives will not be present at the meeting room.Questions at the meeting will be concentrated on the decision points on the agenda and other information that the participants are entitled to receive according to law.The number of people attending who are not shareholders will be limited. Shareholders are therefore requeste

Kallelse till Elanders årsstämma 202027.5.2020 09:00:00 CESTPressemelding

Aktieägarna i Elanders AB (publ) kallas till årsstämma torsdagen den 25 juni 2020, kl. 10.00 på Södra Porten, Flöjelbergsgatan 1 C, Mölndal. INFORMATION MED ANLEDNING AV COVID-19 (CORONAVIRUSET) Mot bakgrund av den pågående smittspridningen av coronaviruset kommer ett antal säkerhetsåtgärder att vidtas i samband med årsstämman för att minska risken för aktieägare och andra som deltar vid stämman: Inregistreringen kommer inte att påbörjas förrän kl. 09.30.Ingen mat eller dryck kommer att serveras och inga gåvor kommer att delas ut.Anförandet av verkställande direktören kommer att hållas mycket kort.Styrelsen och bolagsledningen kommer, med några få undantag, inte närvara i stämmolokalen.Frågor på stämman kommer att koncentreras till beslutspunkterna på dagordningen och andra upplysningar som deltagarna har rätt att erhålla enligt lag.Antalet deltagare som inte är aktieägare kommer att begränsas. Aktieägare ombeds därför också att, om möjligt, avstå från att ta med biträden.Aktieägare up

Electra Gruppen kallar till Årsstämma27.5.2020 08:30:00 CESTPressemelding

ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 Pressmeddelande 2020-05-27 Electra Gruppen kallar till Årsstämma Electra Gruppen kallar till årsstämma. Stämman äger rum den 25 juni kl. 11.00 i Electras lokaler på Trångsundsvägen 20 i Kalmar. Kallelse till stämman återfinns på bolagets hemsida, www.electra.se samt är även publicerad i Post- och Inrikes tidningar. På hemsidan återfinns även material som ska finnas tillgängligt för aktieägare och intressenter samt fullmaktsunderlag. Som en konsekvens av Covid-19 pandemin önskar vi genomföra bolagstämman med så få fysiskt närvarande personer som möjligt. Aktieägare kommer beredas möjlighet att utöva sina rättigheter som aktieägare på annat sätt via deltagande digitalt på distans eller liknande upplägg. Information om detta kommer meddelas via bolagets hemsida senast 1 vecka innan stämmans genomförande. I kallelsen framgår att styrelsen föreslår stämman att ingen utdelning lämnas. Styrelsen kommunicerar att trots att Bolagets resultatutvecklin

CEO review at Cargotec's Annual General Meeting27.5.2020 08:15:00 CESTPress release

CEO review at Cargotec's Annual General Meeting CARGOTEC CORPORATION, PRESS RELEASE, 27 MAY 2020 AT 9:15 AM (EEST) Cargotec Corporation's Annual General Meeting will be held today, 27 May 2020, at 1.00 p.m. Finnish time in Helsinki, Finland. The CEO review will focus on Cargotec’s financial results in 2019, company performance during the first quarter of 2020, and Cargotec’s climate ambition. The CEO review does not include any material new information. The presentation material is attached to this press release and is also available at www.cargotec.com. A video recording of the CEO review is available at Cargotec's website within coming days. Cargotec’s interim report January–March 2020 is available via this link. For further information, please contact: Hanna-Maria Heikkinen, Vice President, Investor Relations, tel. +358 20 777 4084, hanna-maria.heikkinen@cargotec.com Cargotec (Nasdaq Helsinki: CGCBV) enables smarter cargo flow for a better everyday with its leading cargo handling so